Accuracy of Anti-SARS-CoV-2 Antibody in Comparison with Surrogate Viral Neutralization Test in Persons Living with HIV, Systemic Lupus Erythematosus, and Chronic Kidney Disease

Author:

Tiara Marita Restie12,Prayuda Chrisan Bimo1ORCID,Maulidya Tara Titian1,Djauhari Hofiya1,Suhendar Dadang3,Wisaksana Rudi14,Hamijoyo Laniyati5,Supriyadi Rudi6,Indrati Agnes Rengga17ORCID,Alisjahbana Bachti14ORCID

Affiliation:

1. Research Center for Care and Control of Infectious Disease, Universitas Padjadjaran, Bandung 40161, Indonesia

2. Mayapada Hospital Buah Batu, Bandung 40266, Indonesia

3. Research Center for Applied Microbiology, National Research and Innovation Agency (BRIN), KST Soekarno, Cibinong, Jl. Raya Jakarta—Bogor KM 46, Cibinong 16911, Indonesia

4. Infectious and Tropical Disease Division, Internal Medicine Department, Hasan Sadikin Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40261, Indonesia

5. Rheumatology Division, Department of Internal Medicine, Hasan Sadikin Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia

6. Nephrology and Hypertension Division, Internal Medicine Department, Hasan Sadikin Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia

7. Clinical Pathology Department, Hasan Sadikin Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia

Abstract

The presence of the anti-SARS-CoV-2-RBD antibody (anti-RBD) prevents severe COVID-19. We aimed to determine the accuracy of a point-of-care anti-RBD testing implemented in persons living with HIV (PLWH), systemic lupus erythematosus (SLE), and chronic kidney disease (CKD). We enrolled 182 non-comorbid subjects and 335 comorbid subjects (PLWH, SLE, CKD) to test the anti-RBD assay compared to the surrogate viral neutralization test (sVNT) as the reference test. We performed linear correlation analysis between anti-RBD and sVNT, along with an ROC analysis to ascertain the anti-RBD cutoff at 30%, 60%, and 90% inhibition of sVNT, to calculate accuracy. The correlations between anti-RBD and sVNT among all groups were excellent, with R = 0.7903, R = 0.7843, and R = 0.8153 among the non-comorbid, SLE, and CKD groups, respectively, and with significantly higher correlation among the PLWH group (R = 0.8877; p-value = 0.0072) compared to the non-comorbid group. The accuracy of the anti-RBD test among the PLWH and CKD groups was similar to that among the non-comorbid group but showed lower sensitivity in the SLE group (p = 0.000014). The specificity of the test remained high in all groups. In conclusion, the anti-RBD test had excellent correlation with the sVNT. The persistently high specificity in all groups suggests that this test can be reliably utilized to detect the presence of low neutralization capacity, prompting additional vaccination.

Funder

Indonesian National Research and Innovation Agency

Wondfo, Guangzhou Biotech Co., Ltd., China and PT Biofarma Indonesia

Publisher

MDPI AG

Reference26 articles.

1. COVID-19: Transmission, Prevention, and Potential Therapeutic Opportunities;Lotfi;Clin. Chim. Acta,2020

2. WHO Declares COVID-19 a Pandemic;Cucinotta;Acta Biomed.,2020

3. What Is the Vaccine Effect on Reducing Transmission in the Context of the SARS-CoV-2 Delta Variant?;Lancet Infect. Dis.,2022

4. Effectiveness and Safety of SARS-CoV-2 Vaccine in Real-World Studies: A Systematic Review and Meta-Analysis;Liu;Infect. Dis. Poverty,2021

5. Efficacy of COVID-19 Vaccines in Immunocompromised Patients: Systematic Review and Meta-Analysis;Wong;BMJ,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3